Transcarent, a health tech unicorn co-founded by Glen Tullman, has successfully raised $126 million in a Series D funding round. The round was led by General Catalyst and 7wireVentures. This new influx of capital, which values Transcarent at $2.2 billion, is earmarked for advancing AI projects and strategic acquisitions. The funding signifies a positive shift in the health tech funding landscape, suggesting a market rebound.
Digital health startup Transcarent notched a valuation of $2.2 billion after its latest fund raise, led by General Catalyst and 7wireVentures, amid signs of a rebound in the funding market. https://t.co/5pSRyzoIdN https://t.co/5pSRyzoIdN
Digital health startup Transcarent notched a valuation of $2.2 billion after its latest fund raise, led by General Catalyst and 7wireVentures, amid signs of a rebound in the funding market. https://t.co/hFx4S1ddDd https://t.co/hFx4S1ddDd
We’re thrilled to further our partnership with @GlenTullman & the @transcarent team by co-leading its $126M Series D raise. Glen & @htaneja co-created Transcarent with the vision to transform the delivery of health & care. More from @statnews ↓ https://t.co/LT1DdjV4l6
The new funding led by General Catalyst and 7wireVentures values Transcarent at $2.2 billion, will be used for AI projects, acquisitions. https://t.co/piELJIVyWm
New: Transcarent, Glen Tullman’s health tech unicorn, raises $126 million https://t.co/5qGfHl3ejs